American Journal of Cardiovascular Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects
ConclusionThe results of this study suggest that diabetic patients with hypertension receiving both metformin and baxdrostat are unlikely to require dose adjustment.RegistrationClinicalTrials.gov identifier no. NCT05526690.Graphical Abstract (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 15, 2023 Category: Cardiology Source Type: research

CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials
ConclusionsCarriers of aCYP2C9 *2 or *3 LoF allele presenting with acute coronary syndrome and treated with clopidogrel did not have an increased risk for thrombotic events compared with noncarriers. Given the limited number of poor metabolizers, no firm conclusions could be drawn with regard to the thrombotic risk for patients carrying two CYP2C9 LoF alleles. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 14, 2023 Category: Cardiology Source Type: research

Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States
ConclusionsThe clinical characteristics of patients with ATTRwt-CM who were prescribed tafamidis in the real world were broadly comparable with those who took part in ATTR-ACT. Further studies are needed to evaluate hereditary and ATTRwt-CM patient populations in the real world and assess the long-term outcomes associated with disease management pathways.Clinical Trials RegistrationClinicalTrials.gov identifier: NCT01994889. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 13, 2023 Category: Cardiology Source Type: research

Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study
ConclusionsFiribastat was not superior to ramipril for prevention of left ventricular dysfunction after first acute anterior MI, and their safety profiles were similar.RegistrationClinicalTrials.gov identifier NCT03715998. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 9, 2023 Category: Cardiology Source Type: research

Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure
ConclusionEarly administration of TLV in patients with predicted poor DR contributed to a significant diuretic effect and suppression of worsening renal function. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 4, 2023 Category: Cardiology Source Type: research

Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country
ConclusionsIn a developing country where suboptimal anticoagulation control is common, apixaban was the cost-effective alternative to warfarin for patients with both low and intermediate TTR control. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 3, 2023 Category: Cardiology Source Type: research

Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review
ConclusionsBased on the results of the present study, the addition of dapagliflozin to standard care in patients with HFrEF was cost effective. More studies investigating the cost effectiveness of dapagliflozin in patients with HFrEF are required in light of the actual epidemiological data of countries in the relevant input parameters. It is also recommended to conduct cost-effectiveness studies of dapagliflozin taking into account costs and benefits from a societal perspective. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - February 1, 2023 Category: Cardiology Source Type: research

Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation
ConclusionAfter an AV node ablation, the use of BB is associated with an increased risk of HF hospitalizations in a cohort of elderly patients. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 18, 2023 Category: Cardiology Source Type: research

Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes
ConclusionsAs part of an integrative risk assessment, this study demonstrated no clinically relevant corrected QT prolongation with vericiguat 10 mg once daily at steady state.Clinical Trial RegistrationClinicalTrials.gov number, NCT03504982.Graphical Abstract (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 12, 2023 Category: Cardiology Source Type: research

Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial
ConclusionTecarfarin was well-tolerated by Chinese volunteers. Dose titration was needed for tecarfarin doses larger than 20  mg to keep the INR in the target range.RegistrationClinicalTrials.gov identifier: NCT04627116. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 9, 2023 Category: Cardiology Source Type: research

Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
ConclusionsSodium-glucose cotransporter inhibitors  significantly reduced major adverse cardiovascular events, including hospitalization and all-cause mortality in patients with or without established atherosclerotic cardiovascular disease. We observed a beneficial trend in patients with heart failure with preserved ejection fraction, and no benefi ts in patients with stroke or myocardial infarction. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 27, 2022 Category: Cardiology Source Type: research

Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis
ConclusionsVSDAPT significantly decreased the odds of NACEs and major bleeding by 17% and 29%, respectively, without increasing ischemic events. Thus, VSDAPT could be well tolerated and feasible after PCI with DES.Clinical Trials RegistrationOpen Science Framework (10.17605/OSF.IO/4H2JB)Graphical AbstractVery short-term DAPT significantly reduces NACE and major bleedings, without affecting mortality and ischemic events (MACE, MI, stroke, stent thrombosis and revascularization).CI confidence intervals,DAPT dual antiplatelet therapy,DES drug-eluting stents,MACE major adverse cardiovascular events,MI myocardial infarction,NAC...
Source: American Journal of Cardiovascular Drugs - December 20, 2022 Category: Cardiology Source Type: research

Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment
This article aims to highlight the dosing issues of direct oral anticoagulants (DOACs) in patients with renal impairment and/or obesity in an attempt to develop solutions employing advanced data-driven techniques. DOACs have become widely accepted by clinicians worldwide because of their superior clinical profiles, more predictable pharmacokinetics, and hence more convenient dosing relative to other anticoagulants. However, the optimal dosing of DOACs in extreme bodyweight   patients and patients with renal impairment is difficult to achieve using the conventional dosing approach. The standard dosing approach (fixed-dose)...
Source: American Journal of Cardiovascular Drugs - December 14, 2022 Category: Cardiology Source Type: research

Adherence and Discontinuation of Disease-Specific Therapies for  Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
ConclusionsIn the real world, a considerable proportion of patients prescribed PAH-specific therapies were non-adherent or discontinued. As diverse factors may influence treatment adherence, multifaceted interventions are needed to address this trend in order to improve patient outcomes.RegistrationThe systematic review protocol was registered in the PROSPERO database (CRD42022316638). (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - November 25, 2022 Category: Cardiology Source Type: research

Statins Reduce Bleeding Risk in Patients Taking Oral Anticoagulants for Nonvalvular Atrial Fibrillation: A Retrospective Registry Study
ConclusionsStatins significantly reduced the risk of major bleeding, all-cause mortality, and ischemic events in patients with NVAF taking OACs. Their additive benefits should be considered in routine practice and thus be further researched. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - November 16, 2022 Category: Cardiology Source Type: research